Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer

BMC Medical Genomics

Volumn 2, Issue , 2009, Pages

  Li, Meng ^a   Balch, Curt ^a,b,c   Montgomery, John S ^a   Jeong, Mikyoung ^d   Chung, Jae Hoon ^d   Yan, Pearlly ^e   Huang, Tim Hm ^e   Kim, Sun ^f,g   Nephew, Kenneth P ^a,b,c  

^a Indiana University School of Medicine   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f INDIANA UNIVERSITY   (United States)

^g INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER RESISTANCE; CELL ADHESION; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DNA DETERMINATION; DNA METHYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIGHT JUNCTION;

EID: 68249159896     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-2-34     Document Type: Article

References (91)

1. SEER Cancer Statistics Review. LAG Ries D Melbert M Krapcho DG Stinchcomb N Howlader MJ Horner A Mariotto BA Miller EJ Feuer SF Altekruse, National Cancer Institute. Bethesda, MD 1975 http://seer.cancer.gov/csr/1975-2005/
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. WP McGuire WJ Hoskins MF Brady PR Kucera EE Partridge KY Look DL Clarke-Pearson M Davidson, N Engl J Med 1996 334 1 1 6 10.1056/NEJM199601043340101 7494563 (Pubitemid 26012496)
3. Treatment goals in ovarian cancer. RF Ozols, Int J Gynecol Cancer 2005 15 Suppl 1 3 11 10.1111/j.1525-1438.2005.15351.x 15839952 (Pubitemid 40696471)
4. Ovarian cancer: strategies for overcoming resistance to chemotherapy. R Agarwal SB Kaye, Nat Rev Cancer 2003 3 7 502 516 10.1038/nrc1123 12835670
5. Mechanisms of resistance to cisplatin and carboplatin. DJ Stewart, Crit Rev Oncol Hematol 2007 63 1 12 31 10.1016/j.critrevonc.2007.02.001 17336087 (Pubitemid 46810280)
6. DNA-based drug interactions of cisplatin. M Crul RC van Waardenburg JH Beijnen JH Schellens, Cancer Treat Rev 2002 28 6 291 303 10.1016/S0305-7372(02) 00093-2 12470980 (Pubitemid 36054538)
7. Biochemical mechanisms of cisplatin cytotoxicity. V Cepeda MA Fuertes J Castilla C Alonso C Quevedo JM Perez, Anticancer Agents Med Chem 2007 7 1 3 18 10.2174/187152007779314044 17266502
8. The resurgence of platinum-based cancer chemotherapy. L Kelland, Nat Rev Cancer 2007 7 8 573 584 10.1038/nrc2167 17625587
9. Cisplatin: mode of cytotoxic action and molecular basis of resistance. ZH Siddik, Oncogene 2003 22 47 7265 7279 10.1038/sj.onc.1206933 14576837 (Pubitemid 37487159)
10. The epigenetics of ovarian cancer drug resistance and resensitization. C Balch TH Huang R Brown KP Nephew, Am J Obstet Gynecol 2004 191 5 1552 1572 10.1016/j.ajog.2004.05.025 15547525 (Pubitemid 39491180)
11. The history of cancer epigenetics. AP Feinberg B Tycko, Nat Rev Cancer 2004 4 2 143 153 10.1038/nrc1279 14732866
12. Strategies for reversing drug resistance. T Fojo S Bates, Oncogene 2003 22 47 7512 7523 10.1038/sj.onc.1206951 14576855 (Pubitemid 37487173)
13. The epigenomics of cancer. PA Jones SB Baylin, Cell 2007 128 4 683 692 10.1016/j.cell.2007.01.029 17320506 (Pubitemid 46273572)
14. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. PA Konstantinopoulos E Fountzilas K Pillay L Zerbini TA Libermann SA Cannistra D Spentzos, BMC Med Genomics 2008 1 1 59 19038057 10.1186/1755-8794-1-59
15. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. D Takai PA Jones, Proc Natl Acad Sci USA 2002 99 6 3740 3745 11891299 10.1073/pnas.052410099 (Pubitemid 34252176)
16. New anti-cancer strategies: epigenetic therapies and biomarkers. C Balch JS Montgomery HI Paik S Kim TH Huang KP Nephew, Front Biosci 2005 10 1897 1931 10.2741/1668 15769674
17. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. R Brown GL Hirst WM Gallagher AJ McIlwrath GP Margison AG van der Zee DA Anthoney, Oncogene 1997 15 1 45 52 10.1038/sj.onc.1201167 9233776
18. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. JM Cunningham ER Christensen DJ Tester CY Kim PC Roche LJ Burgart SN Thibodeau, Cancer Res 1998 58 15 3455 3460 9699680
19. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Y Kitajima K Miyazaki S Matsukura M Tanaka M Sekiguchi, Gastric Cancer 2003 6 2 86 95 12861399
20. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. M Martini M Ciccarone G Garganese C Maggiore A Evangelista S Rahimi G Zannoni G Vittori LM Larocca, Int J Cancer 2002 102 4 398 406 10.1002/ijc.10715 12402310 (Pubitemid 35265880)
21. Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. W Dai JM Teodoridis J Graham C Zeller TH Huang P Yan JK Vass R Brown J Paul, BMC Bioinformatics 2008 9 337 18691414 10.1186/1471-2105-9-337
22. Prognostic DNA methylation biomarkers in ovarian cancer. SH Wei C Balch HH Paik YS Kim RL Baldwin S Liyanarachchi L Li Z Wang JC Wan RV Davuluri, Clin Cancer Res 2006 12 9 2788 2794 10.1158/1078-0432.CCR-05-1551 16675572 (Pubitemid 43752118)
23. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. SH Wei CM Chen G Strathdee J Harnsomburana CR Shyu F Rahmatpanah H Shi SW Ng PS Yan KP Nephew, Clin Cancer Res 2002 8 7 2246 2252 12114427
24. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. GS Watts BW Futscher N Holtan K Degeest FE Domann SL Rose, BMC Med Genomics 2008 1 47 18826610 10.1186/1755-8794-1-47
25. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. DS Hsu BS Balakumaran CR Acharya V Vlahovic KS Walters K Garman C Anders RF Riedel J Lancaster D Harpole, J Clin Oncol 2007 25 28 4350 4357 10.1200/JCO.2007.11.0593 17906199 (Pubitemid 350013839)
26. A genomic approach to identify molecular pathways associated with chemotherapy resistance. RF Riedel A Porrello E Pontzer EJ Chenette DS Hsu B Balakumaran A Potti J Nevins PG Febbo, Mol Cancer Ther 2008 7 10 3141 3149 10.1158/1535-7163.MCT-08-0642 18852117
27. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. JJ Stewart JT White X Yan S Collins CW Drescher ND Urban L Hood B Lin, Mol Cell Proteomics 2006 5 3 433 443 16319398
28. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. XD Yan LY Pan Y Yuan JH Lang N Mao, Journal of proteome research 2007 6 2 772 780 10.1021/pr060402r 17269733 (Pubitemid 46340180)
29. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. M Prasad M Bernardini A Tsalenko P Marrano J Paderova CH Lee A Ben-Dor MT Barrett JA Squire, Genes, chromosomes & cancer 2008 47 5 427 436 10.1002/gcc.20547 18273836
30. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. VM Wasenius A Jekunen O Monni H Joensuu S Aebi SB Howell S Knuutila, Genes, chromosomes & cancer 1997 18 4 286 291 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X 9087568
31. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. C Balch P Yan T Craft S Young DG Skalnik TH Huang KP Nephew, Molecular cancer therapeutics 2005 4 10 1505 1514 10.1158/1535-7163.MCT-05-0216 16227399 (Pubitemid 41556432)
32. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. M Fan PS Yan C Hartman-Frey L Chen H Paik SL Oyer JD Salisbury AS Cheng L Li PH Abbosh, Cancer Res 2006 66 24 11954 11966 10.1158/0008-5472. CAN-06-1666 17178894 (Pubitemid 46094209)
33. Differential methylation hybridization using CpG island arrays. PS Yan SH Wei TH Huang, Methods Mol Biol 2002 200 87 100 11951657
34. Applications of CpG island microarrays for high-throughput analysis of DNA methylation. PS Yan CM Chen H Shi F Rahmatpanah SH Wei TH Huang, J Nutr 2002 132 8 Suppl 2430S 2434S 12163706
35. Bioconductor: open software development for computational biology and bioinformatics. RC Gentleman VJ Carey DM Bates B Bolstad M Dettling S Dudoit B Ellis L Gautier Y Ge J Gentry, Genome Biol 2004 5 10 R80 15461798 10.1186/gb-2004-5-10-r80
36. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Y Benjamini Y Hochberg, Journal of the Royal Statistical Society Series B (Methodological) 1995 57 1 289 300
37. The control of the false discovery rate in multiple testing under dependency. Y Benjamini D Yekutieli, Ann Stat 2001 29 1165 1168 10.1214/aos/1013699998 (Pubitemid 33575263)
38. Analysis of gene expression in pathophysiological states: balancing false discovery and false negative rates. AW Norris CR Kahn, Proc Natl Acad Sci USA 2006 103 3 649 653 16407153 10.1073/pnas.0510115103 (Pubitemid 43153080)
39. Cluster analysis and display of genome-wide expression patterns. MB Eisen PT Spellman PO Brown D Botstein, Proc Natl Acad Sci USA 1998 95 25 14863 14868 9843981 10.1073/pnas.95.25.14863 (Pubitemid 29003722)
40. Onto-Tools (The Intelligent Systems and Bioinformatics Laboratory). http://vortex.cs.wayne.edu/Projects.html
41. A systems biology approach for pathway level analysis. S Draghici P Khatri AL Tarca K Amin A Done C Voichita C Georgescu R Romero, Genome Res 2007 17 10 1537 1545 17785539 10.1101/gr.6202607 (Pubitemid 47529438)
42. KEGG: Kyoto Encyclopedia of Genes and Genomes. http://www.genome.jp/kegg/ pathway.html
43. DAVID: Database for Annotation, Visualization, and Integrated Discovery. G Dennis Jr BT Sherman DA Hosack J Yang W Gao HC Lane RA Lempicki, Genome Biol 2003 4 5 P3 10.1186/gb-2003-4-5-p3 12734009
44. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. W Huang da BT Sherman RA Lempicki, Nat Protoc 2009 4 1 44 57 10.1038/nprot.2008.211 19131956
45. Database for Annotation, Visualization and Integrated Discovery (DAVID). http://david.abcc.ncifcrf.gov/
46. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. A Eva KC Robbins PR Andersen A Srinivasan SR Tronick EP Reddy NW Ellmore AT Galen JA Lautenberger TS Papas, Nature 1982 295 5845 116 119 10.1038/295116a0 6173755
47. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. BC Behrens TC Hamilton H Masuda KR Grotzinger J Whang-Peng KG Louie T Knutsen WM McKoy RC Young RF Ozols, Cancer Res 1987 47 2 414 418 3539322
48. Cancer epigenetics: modifications, screening, and therapy. EN Gal-Yam Y Saito G Egger PA Jones, Annu Rev Med 2008 59 267 280 10.1146/annurev.med.59. 061606.095816 17937590 (Pubitemid 351287937)
49. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. JC Cheng DJ Weisenberger FA Gonzales G Liang GL Xu YG Hu VE Marquez PA Jones, Mol Cell Biol 2004 24 3 1270 1278 14729971 10.1128/MCB.24.3.1270-1278.2004 (Pubitemid 38112188)
50. Drug reactivates genes to inhibit cancer. V Foubister, Drug Discov Today 2003 8 10 430 431 10.1016/S1359-6446(03)02697-7 12801788 (Pubitemid 36683270)
51. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. M Ashburner CA Ball JA Blake D Botstein H Butler JM Cherry AP Davis K Dolinski SS Dwight JT Eppig, Nat Genet 2000 25 1 25 29 10.1038/75556 10802651 (Pubitemid 30257031)
52. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. D Lebwohl R Canetta, Eur J Cancer 1998 34 10 1522 1534 10.1016/S0959-8049(98)00224-X 9893623 (Pubitemid 28446332)
53. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. DE Lamendola Z Duan RZ Yusuf MV Seiden, Cancer Res 2003 63 9 2200 2205 12727840
54. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. M Sakamoto A Kondo K Kawasaki T Goto H Sakamoto K Miyake Y Koyamatsu T Akiya H Iwabuchi T Muroya, Hum Cell 2001 14 4 305 315 11925933
55. Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells. M Li HI Paik C Balch Y Kim L Li TH Huang KP Nephew S Kim, Bioinformatics 2008 24 16 1745 1748 10.1093/ bioinformatics/btn256 18540022
56. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. I Rhee KE Bachman BH Park KW Jair RW Yen KE Schuebel H Cui AP Feinberg C Lengauer KW Kinzler, Nature 2002 416 6880 552 556 10.1038/416552a 11932749 (Pubitemid 34288859)
57. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. KD Robertson E Uzvolgyi G Liang C Talmadge J Sumegi FA Gonzales PA Jones, Nucleic Acids Res 1999 27 11 2291 2298 10325416 10.1093/nar/27.11.2291 (Pubitemid 29245646)
58. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. MV Mishra KS Bisht L Sun K Muldoon-Jacobs R Awwad A Kaushal P Nguyen L Huang JD Pennington S Markovina, Mol Cancer Res 2008 6 2 243 249 10.1158/1541-7786.MCR-07-0373 18314485 (Pubitemid 351342412)
59. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. JA Plumb G Strathdee J Sludden SB Kaye R Brown, Cancer Res 2000 60 21 6039 6044 11085525
60. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. YY Qiu BL Mirkin RS Dwivedi, Cancer Detect Prev 2005 29 5 456 463 10.1016/j.cdp.2005.05.004 16185816 (Pubitemid 41406141)
61. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. G Strathdee MJ MacKean M Illand R Brown, Oncogene 1999 18 14 2335 2341 10.1038/sj.onc.1202540 10327053
62. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. A Ahluwalia JA Hurteau RM Bigsby KP Nephew, Gynecol Oncol 2001 82 2 299 304 10.1006/gyno.2001.6284 11531283 (Pubitemid 32730607)
63. Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. M Ehrlich CB Woods MC Yu L Dubeau F Yang M Campan DJ Weisenberger T Long B Youn ES Fiala, Oncogene 2006 25 18 2636 2645 16532039 10.1038/sj.onc.1209145
64. CpG island methylation of DNA damage response genes in advanced ovarian cancer. JM Teodoridis J Hall S Marsh HD Kannall C Smyth J Curto N Siddiqui H Gabra HL McLeod G Strathdee, Cancer Res 2005 65 19 8961 8967 10.1158/0008-5472.CAN-05-1187 16204069 (Pubitemid 41377387)
65. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Y Xiong SC Dowdy A Xue J Shujuan NL Eberhardt KC Podratz SW Jiang, Gynecol Oncol 2005 96 3 601 609 10.1016/j.ygyno.2004.11.047 15721400 (Pubitemid 40255476)
66. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? SH Wei R Brown TH Huang, Annals of the New York Academy of Sciences 2003 983 243 250 12724229
67. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. J Nyce S Leonard D Canupp S Schulz S Wong, Proc Natl Acad Sci USA 1993 90 7 2960 2964 8464912 10.1073/pnas.90.7.2960
68. Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. J Nyce L Liu PA Jones, Nucleic Acids Res 1986 14 10 4353 4367 3086840 10.1093/nar/14.10.4353
69. Recruitment of DNA methyltransferase I to DNA repair sites. O Mortusewicz L Schermelleh J Walter MC Cardoso H Leonhardt, Proc Natl Acad Sci USA 2005 102 25 8905 8909 15956212 10.1073/pnas.0501034102 (Pubitemid 40881051)
70. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. V Valinluck LC Sowers, Cancer Res 2007 67 3 946 950 10.1158/0008-5472.CAN-06-3123 17283125 (Pubitemid 46270748)
71. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/search
72. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. JF Costello MC Fruhwald DJ Smiraglia LJ Rush GP Robertson X Gao FA Wright JD Feramisco P Peltomaki JC Lang, Nat Genet 2000 24 2 132 138 10.1038/72785 10655057 (Pubitemid 30094712)
73. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. K Matter S Aijaz A Tsapara MS Balda, Curr Opin Cell Biol 2005 17 5 453 458 10.1016/j.ceb.2005.08.003 16098725 (Pubitemid 41267158)
74. Signalling to and from tight junctions. K Matter MS Balda, Nat Rev Mol Cell Biol 2003 4 3 225 236 10.1038/nrm1055 12612641 (Pubitemid 36288044)
75. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. PJ Morin, Cancer Res 2005 65 21 9603 9606 10.1158/0008-5472.CAN-05- 2782 16266975 (Pubitemid 41541431)
76. Regulation of the CLDN3 gene in ovarian cancer cells. H Honda MJ Pazin T D'Souza H Ji PJ Morin, Cancer Biol Ther 2007 6 11 1733 1742 17986852
77. Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. F Nakayama S Semba Y Usami H Chiba N Sawada H Yokozaki, Pathobiology 2008 75 3 177 185 10.1159/000124978 18550915
78. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. M Osanai M Murata H Chiba T Kojima N Sawada, Cancer Sci 2007 98 10 1557 1562 10.1111/j.1349-7006.2007.00569.x 17645772 (Pubitemid 47308450)
79. DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. S Boireau M Buchert MS Samuel J Pannequin JL Ryan A Choquet H Chapuis X Rebillard C Avances M Ernst, Carcinogenesis 2007 28 2 246 258 10.1093/carcin/bgl120 16829686 (Pubitemid 46321840)
80. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. B Litkouhi J Kwong CM Lo JG Smedley 3rd BA McClane M Aponte Z Gao JL Sarno J Hinners WR Welch, Neoplasia 2007 9 4 304 314 17460774 10.1593/neo.07118 (Pubitemid 46608297)
81. alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. S Cruet-Hennequart S Maubant J Luis P Gauduchon C Staedel S Dedhar, Oncogene 2003 22 11 1688 1702 10.1038/sj.onc. 1206347 12642872 (Pubitemid 36408184)
82. Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. S Maubant S Cruet-Hennequart L Poulain F Carreiras F Sichel J Luis C Staedel P Gauduchon, Int J Cancer 2002 97 2 186 194 10.1002/ijc.1600 11774263 (Pubitemid 34019954)
83. Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation? P Mazzarelli S Pucci E Bonanno F Sesti M Calvani LG Spagnoli, Cancer Biol Ther 2007 6 10 1606 1613 18253084
84. Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway. YL Pon N Auersperg AS Wong, J Biol Chem 2005 280 15 15438 15448 10.1074/jbc.M410766200 15701645 (Pubitemid 40562902)
85. Exploiting the PI3K/AKT pathway for cancer drug discovery. BT Hennessy DL Smith PT Ram Y Lu GB Mills, Nat Rev Drug Discov 2005 4 12 988 1004 10.1038/nrd1902 16341064
86. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. L Zhang J Huang N Yang J Greshock S Liang K Hasegawa A Giannakakis N Poulos A O'Brien-Jenkins D Katsaros, Clin Cancer Res 2007 13 18 Pt 1 5314 5321 10.1158/1078-0432.CCR-06-2660 17875760 (Pubitemid 47510355)
87. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. HK Dressman A Berchuck G Chan J Zhai A Bild R Sayer J Cragun J Clarke RS Whitaker L Li, J Clin Oncol 2007 25 5 517 525 10.1200/JCO.2006.06.3743 17290060 (Pubitemid 350002958)
88. Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. D Reimer S Sadr A Wiedemair S Stadlmann N Concin G Hofstetter E Muller-Holzner C Marth AG Zeimet, Clin Cancer Res 2007 13 1 144 151 10.1158/1078-0432.CCR-06-0780 17200349 (Pubitemid 46121863)
89. Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation. A Wang CJ Li PV Reddy AB Pardee, Cancer Res 2005 65 17 7809 7814 16140949
90. Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines. G Chen P Ghosh H Osawa CY Sasaki L Rezanka J Yang TJ O'Farrell DL Longo, Blood 2007 109 12 5301 5307 17339425 10.1182/blood-2006-06-032128 (Pubitemid 46890551)
91. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. VF Chekhun NY Lukyanova O Kovalchuk VP Tryndyak IP Pogribny, Mol Cancer Ther 2007 6 3 1089 1098 10.1158/1535-7163.MCT-06-0663 17363502 (Pubitemid 46554580)